Mbx-8025

Primary Sclerosing Cholangitis

Gilead SciencesPhase 2Dormant

CCC

52/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 81/ 100

Competitive context

22 Active assets in the Primary Sclerosing Cholangitis cohort.

Asset / Sponsor	Phase	Rating
Vancomycin Tampere University Hospital	Phase 4	BB
URSODEOXYCHOLIC ACID Assistance Publique - Hôpitaux de Paris	Phase 3	BB
Aldafermin NGM Biopharmaceuticals, Inc	Phase 2/3	B
Elafibranor Ipsen	Phase 3	B
htd1801 HighTide Biopharma Pty Ltd	Phase 2	B

View all 50 →

Same molecule, other indications

Mbx-8025 is also rated in:

primary biliary cholangitisDormant

BB

Indicative ·

68 / 100

hyperlipidemiaDormant

CCC

Indicative ·

54 / 100

metabolic dysfunction-associated steatohepatitisDormant

CCC

Indicative ·

52 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.